Novo Nordisk comeback stirs as Wegovy pill wins UK approval
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Novo Nordisk’s Wegovy (semaglutide) pill, marking another…
Novo’s Wegovy Pill Isn’t Just Beating Expectations — It’s Obliterating Them. Is the Beaten-Down Stock a Buy Now?
The pharmaceutical industry is highly competitive and driven by innovation. Those two facts couldn’t be on any clearer…
New Weight Loss Drug Could Beat Ozempic’s Results—When It’s Coming
A new experimental weight loss drug from Eli Lilly could produce greater weight loss results than popular medications…
Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike
The global geopolitical landscape has plunged into a deep state of uncertainty once again following a direct exchange…
Can Wegovy Pill’s Rapid Uptake Give Novo Nordisk an Edge Over LLY?
Novo Nordisk NVO remains one of the dominant players in the rapidly expanding obesity treatment market. The company markets…
3 Reasons Eli Lilly Remains a Buy
Eli Lilly (NYSE: LLY) became the first $1 trillion pharmaceutical company late last year, built on the strength…
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
The pharmaceutical industry is highly technical and incredibly competitive. That is on clear display right now in the…
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic’s AI Leap As Lilly, WeightWatchers Turn Up The Heat
CEO Andrew Dudum called Anthropic’s latest AI breakthrough “transformative” for population health, saying AI is moving “from super…
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible signal to …
US pharmaceutical giant Eli Lilly has announced that it is halving its massive €2.3 billion ($2.67 billion) investment…
Forget Zepbound: Eli Lilly’s Next Billion-Dollar Weight-Loss Drug May Be Even Better
Eli Lilly (NYSE: LLY) has been posting incredible sales and earnings growth in recent quarters, thanks in no…
Weight Loss Drugs Listed By Health Insurers Aren’t Necessarily Covered
Eli Lilly’s Foundayo weight loss oral pill competes against Novo Nordisk’s oral Wegovy. (Photo by: Michael Siluk/UCG/Universal Images…
An experimental GLP-1 pushes the limits of weight loss. There are risks.
Eli Lilly this month unveiled startling new data that showed an experimental weight-loss drug caused people with obesity…